Results 31 to 40 of about 1,153,626 (336)
Dermatologic Clinics, 2015 Use of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Approaches targeting specific cellular targets on the malignant cells and in tumor microenvironment have been proved to be successful in hematologic malignancies, including cutaneous lymphomas.
openaire +3 more sources
Memorias do Instituto Oswaldo Cruz, 1987 We have produced a number of monoclonal antibodies, protective and non-protective, which recognize a complex of schistosomula antigens, including the 38 kDa antigen. Eight different protective and non-protective monoclonal antibodies, varying in isotypes,
Albert I. Ko, Donald A. Harn
doaj +1 more source
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease – history, present, and future. Literature review [PDF]
PharmaciaMonoclonal antibodies (mAbs) are immunoglobulins with practically absolute specificity (monospecificity) for a particular antigen (epitope). Over the past three decades, monoclonal antibodies have undergone a remarkable transformation, evolving from ...
Petar Yordanov Atanasov +11 more
doaj +3 more sources
38227 Specific and highly potent human monoclonal antibodies against SARS-CoV-2
Journal of Clinical and Translational Science, 2021 IMPACT: We devised a new method to produce highly potent SARS-CoV2-specific that can be used to treat severely ill patients with Covid-19. OBJECTIVES/GOALS: Neutralizing antibodies against SARS-CoV-2 are thought to offer the most immediate and effective ...
Mayara Garcia de Mattos Barbosa +4 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell +14 more
wiley +1 more source
Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra
Онкогематология, 2022 Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contraThe review presents the results of a combined analysis of literature data and own clinical observations regarding the safety and feasibility of using ...
K. A. Sychevskaya, S. K. Kravchenko
doaj +1 more source
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Frontiers in Bioengineering and BiotechnologyThe Chinese hamster ovarian (CHO) cells serve as a common choice in biopharmaceutical production, traditionally cultivated in stirred tank bioreactors (STRs).
Xuekun Wang +41 more
doaj +1 more source
Monoclonal Antibodies as Immune Modulators for Cancer Therapy
Canadian Journal of Infectious Diseases, 1992 Monoclonal antibodies may modulate immune and/or biological responses alone, or as carriers of specific agents. Monoclonal antibodies directed against tumours may be indirectly cytotoxic by modulation of antibody-dependent, cell-mediated cytotoxicity or ...
Robert O Dillman
doaj +1 more source